DVT/PE has been the sticking point for baricitinib in RA. DVT/PE risk in integrated safety analysis >8y: incidence doesn't increase, but also doesn't decrease. No diff with dose either. Every drug has pros/cons; it's how we manage risk that counts... #ACR20 ABST0202 @RheumNow https://t.co/V88tQjcXSJ